6.35

7.26% +0.43

Pre-market: 6.02 -0.33 -5.20%

Palisade Bio Inc (PALI)

Overview News Price History Discussions Forecast Stock Split

Palisade Bio Inc stock is currently priced at $6.35, with a 24-hour trading volume of 458.24K. It has seen a +7.26% increased in the last 24 hours and a +1,597% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $6.59 pivot point. If it approaches the $5.00 support level, significant changes may occur.

Previous Close:

$5.92

Open:

$5.69

24h Volume:

458.24K

Market Cap:

$5.41M

Revenue:

Net Income/Loss:

$-12.30M

P/E Ratio:

-0.9874

EPS:

-6.4313

Net Cash Flow:

$-11.13M

1W Performance:

-3.79%

1M Performance:

+1,597%

6M Performance:

+953.24%

1Y Performance:

+299.50%

1D Range:

$5.51

$6.45

52W Range:

$0.3602

$9.65

Palisade Bio Inc Stock (PALI) Company Profile

Name

Palisade Bio Inc

Sector

Healthcare (1198)

Industry

Biotechnology (688)

Phone

858-704-4900

Address

5800 Armada Drive, Suite 210, Carlsbad

Employee

Twitter

Next Earnings Date

2024-05-10

Latest SEC Filings

PALI's Discussions on Twitter

Palisade Bio Inc Stock (PALI) Latest News

Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach

GlobeNewswire Inc.

S&P 500 Edges Lower; PacBio Shares Plunge

Benzinga

Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Palisade Bio Inc Stock (PALI) Financials Data

Palisade Bio Inc (PALI) Net Income 2024

PALI net income (TTM) was -$12.30 million for the quarter ending December 31, 2023, a +13.74% increase year-over-year.

Palisade Bio Inc (PALI) Cash Flow 2024

PALI recorded a free cash flow (TTM) of -$11.13 million for the quarter ending December 31, 2023, a +16.67% increase year-over-year.

Palisade Bio Inc (PALI) Earnings per Share 2024

PALI earnings per share (TTM) was -$1.81 for the quarter ending December 31, 2023, a +92.52% growth year-over-year.

Palisade Bio, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress, such as results from reduced blood flow to the intestine, infections, and surgery. The company was founded in 2005 and is based in Carlsbad, California.